Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Improving the Quality of Life of Hemodialysis Patients with Chronic Kidney Disease-associated Pruritus

Frédérique Menzaghi, PhD

Senior Vice President, Research and Development

Cara Therapeutics Inc., Stamford, CT, USA



CKD-associated Pruritus







- Serious itching condition directly related to kidney disease
 - 60-70% of hemodialysis (HD) patients
- Itching severity associated with worsening Quality of Life (QoL) (social, emotional and physical)
 - Sleep disturbance, depressed mood, increased mortality risk
- Underrecognized by health care providers but a high priority for patients
- Currently, no FDA approved medications and unsatisfactory off label treatments
 - Most common on back, abdomen & arms
 - Typically bilateral



2

Intravenous CR845 (Difelikefalin)

- Novel selective and potent kappa opioid receptor agonist (Ki = 0.32 nM)
 - No activation of mu and delta opioid receptors
- Hydrophilic small D-amino acid synthetic peptide
 - Does not readily enter the CNS
 - Reduced potential for adverse effects mediated by activation central opioid receptors
- Multifactorial etiology and pathophysiology of CKD-aP supports the use of CR845
 - Dysregulated systemic inflammation (eg, high level interleukin--2, C-reactive protein)
 - Endogenous opioid dysregulation ($\uparrow \beta$ endorphin-mu and \downarrow Dynorphin-A-kappa)




Study design

- Double-blind, randomized, placebo-controlled study in 174 HD patients with moderate or severe pruritus (ClinicalTrials.gov NCT02858726)
 - IV bolus Placebo or CR845: 0.5, 1.0, 1.5 mcg/kg
 - Dosing after each dialysis (3x/week) for 8 weeks
 - Not metabolized and excreted renally
- Multi-center 33 US sites
- Eligibility
 - \geq 18 years or older, HD 3x/week for at least 3 months,
 - Baseline itch intensity >4 [measured during week prior to randomization with numeric rating scale (NRS), 0=no itching up to 10= worst itching imaginable]
 - Patients permitted to use any anti-itch medications they were taking prior randomization
 - Key Exclusion Criteria: non-compliant with HD, anticipated kidney transplant, allergy to opiates, pruritus due to other cause than CKD



Endpoints

Primary: Change from baseline to Week 8 in weekly average of daily 24-hour worst itching intensity NRS score



- Secondary/Exploratory: Change from baseline to Week 8 in itch-related QoL scores using multidimensional questionnaires
 - Skindex-10 (3 domains: disease, mood/emotional/distress, social functioning)
 - 5-D itch scale (5 domains: degree, duration of itch/day, direction [improvement/worse], disability [sleep, social, housework/errands, work/school], and body distribution of itch)
 - Sleep disturbance subscale (MOS sleep)
 - PGIC and PGIS

5

Patient Demographics

Demographics well balanced across all treatment groups

		Placebo (N=45) n (%)	CR845 0.5 mcg/kg (N=44) n (%)	CR845 1.0 mcg/kg (N=41) n (%)	CR845 1.5 mcg/kg (N=44) n (%)			
Gender								
	Female	17	18	18	16			
		(37.8)	(40.9)	(43.9)	(36.4)			
	Male	28	26	23	28			
		(62.2)	(59.1)	(56.1)	(63.6)			
Age, Mean (range)								
		59.0	57.9	58.2	54.1			
		(27 - 84)	(29 - 80)	(26 - 84)	(29 - 74)			
Race								
	Black or African	25	24	22	31			
	American	(55.6)	(54.5)	(53.7)	(70.5)			
	White	16	17	19	10			
		(35.6)	(38.6)	(46.3)	(22.7)			

- 9% of Patients ≥ 75 years old
- Average time on chronic dialysis = 5.8 years; Primary causes of renal failure (diabetes/hypertension)
- Average time with pruritus = 4.4 years




Treatment-Emergent Adverse Events >10% In Any Treatment Group

		CR845	CR845	CR845
Preferred Term	Placebo	0.5 mcg/kg	1.0 mcg/kg	1.5 mcg/kg
	(N=45)	(N=44)	(N=41)	(N=44)
	n (%)	n (%)	n (%)	n (%)
Dizziness	2	6	4	2
	(4.4)	(13.6)	(9.8)	(4.5)
Somnolence	1	2	2	5
	(2.2)	(4.5)	(4.9)	(11.4)
Headache	1	0	5	0
	(2.2)	(0.0)	(12.2)	(0.0)
Diarrhoea	0	7	4	5
	(0.0)	(15.9)	(9.8)	(11.4)
Mental status changes	0	0	1	5
	(0.0)	(0.0)	(2.4)	(11.4)
Nausea	1	5	2	4
	(2.2)	(11.4)	(4.9)	(9.1)



Clinically Meaningful Reduction in Itch Intensity Following an 8-Week Treatment Period with CR845




o EM sis oopulation NRS

≥4-points

*p<0.05, ***p<0.001 vs Placebo

Full Analysis Population: all randomized patients who received at least 1 dose of double-blind study drug.

8




*p<0.05, **p<0.01 vs Placebo, Cochran-Mantel-Haenszel test

24%

51% (*)

Improvement in Itch-related Quality-of-Life Measures Following an 8-Week Treatment Period with CR845




CR845-treated patients exhibited statistically significant improvement across all QoL domains

9

Mean change in QoL measures correlated with the change in itch intensity (Pearson's correlation ranging from r=0.67 to 0.74, p<0.0001).

Reduced Sleep Disturbance Following an 8-Week Treatment Period with CR845



Items contain in the Sleep Disturbance subscale of the MOS Sleep scale:

- Trouble falling asleep
 Awaken during sleep
- Sleep restlessness
 Time to fall asleep



Conclusion

- CR845 was well tolerated and produced a clinically meaningful reduction in itch intensity in hemodialysis patients with moderate or severe CKD-aP
- This reduction was associated with substantial improvement in multiple measures of itch-related quality of life and sleep sustained over 2 months of treatment
- Currently recruiting dialysis sites for initiation of Pivotal Phase 3 trials

CR845 was recently granted Breakthrough Designation for this indication by the FDA

Major need to improve the wellbeing of patients with CKD-aP



Acknowledgment

- Sarbani Bhaduri, MD
- Vandana Marthur, MD
- Catherine Munera, PhD
- Maria Oberdick, BSc
- Adam Russell, BA
- Rob Spencer, PhD
- Joseph Stauffer, DO, MBA

Interested in participating in our program? Contact <u>fmenzaghi@caratherapeutics.com</u>

